Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein

E. Marleen Kemper(Amsterdam University Medical Centers), Olaf van Tellingen(Dutch Cancer Society), Marcel Verheij(Radboud University Nijmegen), Jos H. Beijnen(The Netherlands Cancer Institute), Willem Boogerd(The Netherlands Cancer Institute)
European Journal of Cancer
March 17, 2004
10.1016/j.ejca.2004.01.024
Cited by 120

Related Papers

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
|Cell|1994|2.3k
Genome-wide cell-free DNA fragmentation in patients with cancer
|Nature|2019|1.5k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
|Proceedings of the National Academy of Sciences|1997|941
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
|Proceedings of the National Academy of Sciences|1997|884